Argatroban in the management of heparin-induced thrombocytopenia
Research article published in Vascular health and risk management (2010)
Abstract
Heparin-induced thrombocytopenia (HIT) is an immunoglobulin-mediated serious complication of heparin therapy characterized by thrombocytopenia and high risk for venous and arterial thrombosis: HIT and thrombosis syndrome (HITTS). Argatroban, a direct thrombin inhibitor, is indicated as the anticoagulant for the treatment and prophylaxis of thrombosis in patients with HIT and in patients undergoing percutaneous coronary intervention (PCI) who have HIT. The aim of this review is to examine the pharmacological characteristics and the clinical efficacy and safety of this drug in adults with HIT, including those undergoing PCI. Briefly, 2 prospective multicenter, nonrandomized, open-label studies evaluated the efficacy and safety of argatroban as an anticoagulant in patients with HIT or HITTS. Both studies showed that the incidence of the primary efficacy end point, a composite of all-cause death, all-cause amputation, or new thrombosis, was reduced in argatroban-treated patients vs control subjects with HIT or HITTS. In both studies, bleeding rates were similar between the groups. Argatroban was evaluated as the anticoagulant therapy in 3 prospective, multicenter, open-label studies in HIT patients who underwent PCI. The studies were similar in design with respect to patient inclusion and exclusion criteria, the argatroban dosing regimen, and primary efficacy outcomes. The investigators performed a pooled analysis of these studies, which showed that most (≥95%) patients achieved a satisfactory outcome from the procedure and adequate anticoagulation (coprimary end points).
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Peer-reviewed research on anticoagulant and antithrombotic agents relevant to leech-derived compounds and thrombosis management. Indexed in PubMed and verified against the NCBI record.
Por qué esto importa para la hirudoterapia
Esta revisión examinó la farmacología, la eficacia y la seguridad de argatroban, un inhibidor directo de la trombina, en adultos con trombocitopenia inducida por heparin (HIT) y en pacientes con HIT sometidos a intervención coronaria percutánea; resume dos estudios prospectivos, multicéntricos, no aleatorizados y de etiqueta abierta que reportan un criterio de valoración compuesto reducido (muerte por todas las causas, amputación por todas las causas o nueva trombosis) en comparación con controles con tasas de sangrado comparables, y un análisis agrupado de tres estudios de etiqueta abierta sobre PCI en los que la mayoría de los pacientes (>=95%) lograron resultados procedimentales satisfactorios y una anticoagulación adecuada. Para la hirudoterapia esto es relevante como contexto comparativo: la inhibición directa de la trombina es precisamente el mecanismo del anticoagulante derivado de la sanguijuela hirudin, por lo que argatroban ilustra cómo un inhibidor de trombina de molécula pequeña se posiciona clínicamente frente a la clase de proteínas inspirada en el secretoma. Advertencia: esta es una revisión narrativa de estudios no aleatorizados y de etiqueta abierta de un fármaco sintético, no un ensayo controlado y no un estudio de ninguna molécula derivada de la sanguijuela, por lo que informa sobre el panorama de anticoagulación circundante en lugar de proporcionar evidencia directa para la terapia con sanguijuelas.
Citación
Argatroban in the management of heparin-induced thrombocytopenia.
Babuin et al. · Vascular health and risk management, 2010
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026